Alkotub Bayan, Bauer Lisa, Bashiri Dezfouli Ali, Hachani Khouloud, Ntziachristos Vasilis, Multhoff Gabriele, Kafshgari Morteza Hasanzadeh
Institute of Biological and Medical Imaging (IBMI), Helmholtz Zentrum München, Neuherberg, Germany; Chair of Biological Imaging at the Central Institute for Translational Cancer Research (TranslaTUM), TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Radiation Immuno-Oncology Group, Central Institute for Translational Cancer Research (TranslaTUM), TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.
Radiation Immuno-Oncology Group, Central Institute for Translational Cancer Research (TranslaTUM), TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany; Department of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.
Redox Biol. 2025 Feb;79:103452. doi: 10.1016/j.redox.2024.103452. Epub 2024 Dec 2.
Despite advances in multimodal therapy approaches such as resection, chemotherapy and radiotherapy, the overall survival of patients with grade 4 glioblastoma (GBM) remains extremely poor (average survival time <2 years). Altered lipid metabolism, which increases fatty acid synthesis and thereby contributes to radioresistance in GBM, is a hallmark of cancer. Therefore, we explored the radiosensitizing effect of the clinically approved, lipid-lowering drug fenofibrate (FF) in different GBM cell lines (U87, LN18). Interestingly, FF (50 μM) significantly radiosensitizes U87 cells by inducing DNA double-strand breaks through oxidative stress and impairing mitochondrial membrane integrity, but radioprotects LN18 cells by reducing the production of reactive oxygen species (ROS) and stabilizing the mitochondrial membrane potential. A comparative protein and lipid analysis revealed striking differences in the two GBM cell lines: LN18 cells exhibited a significantly higher membrane expression density of the fatty acid (FA) cluster protein transporter CD36 than U87 cells, a higher expression of glycerol-3-phosphate acyltransferase 4 (GPAT4) which supports the production of large lipid droplets (LDs), and a lower expression of diacylglycerol O-acyltransferase 1 (DGAT1) which regulates the formation of small LDs. Consequently, large LDs are predominantly found in LN18 cells, whereas small LDs are found in U87 cells. After a combined treatment of FF and irradiation, the number of large LDs significantly increased in radioresistant LN18 cells, whereas the number of small LDs decreased in radiosensitive U87 cells. The radioprotective effect of FF in LN18 cells could be associated with the presence of large LDs, which act as a sink for the lipophilic drug FF. To prevent uptake of FF by large LDs and to ameliorate its function as a radiosensitizer, FF was encapsulated in biomimetic cell membrane extracellular lipid vesicles (CmEVs) which alter the intracellular trafficking of the drug. In contrast to the free drug, CmEV-encapsulated FF was predominantly enriched in the lysosomal compartment, causing necrosis by impairing lysosomal membrane integrity. Since the stability of plasma and lysosomal membranes is maintained by the presence of the stress-inducible heat shock protein 70 (Hsp70) which has a strong affinity to tumor-specific glycosphingolipids, necrosis occurs predominantly in LN18 cells having a lower membrane Hsp70 expression density than U87 cells. In summary, our findings indicate that the lipid metabolism of tumor cells can affect the radiosensitizing capacity of FF when encountered either as a free drug or as a drug loaded in biomimetic lipid vesicles.
尽管在多模式治疗方法(如手术切除、化疗和放疗)方面取得了进展,但4级胶质母细胞瘤(GBM)患者的总体生存率仍然极低(平均生存时间<2年)。脂质代谢改变会增加脂肪酸合成,从而导致GBM产生放射抗性,这是癌症的一个标志。因此,我们探究了临床批准的降脂药物非诺贝特(FF)对不同GBM细胞系(U87、LN18)的放射增敏作用。有趣的是,FF(50 μM)通过氧化应激诱导DNA双链断裂并损害线粒体膜完整性,从而显著使U87细胞对辐射敏感,但通过减少活性氧(ROS)的产生并稳定线粒体膜电位来对LN18细胞起到辐射保护作用。一项蛋白质和脂质的对比分析揭示了这两种GBM细胞系存在显著差异:LN18细胞的脂肪酸(FA)簇蛋白转运体CD36的膜表达密度显著高于U87细胞,支持大脂滴(LDs)产生的甘油-3-磷酸酰基转移酶4(GPAT4)表达较高,而调节小脂滴形成的二酰甘油O-酰基转移酶1(DGAT1)表达较低。因此,大脂滴主要存在于LN18细胞中,而小脂滴存在于U87细胞中。在FF与辐射联合处理后,放射抗性的LN18细胞中大脂滴数量显著增加,而放射敏感的U87细胞中小脂滴数量减少。FF对LN18细胞的辐射保护作用可能与大脂滴的存在有关,大脂滴充当亲脂性药物FF的储存库。为了防止大脂滴摄取FF并改善其作为放射增敏剂的功能,将FF包裹在仿生细胞膜细胞外脂质囊泡(CmEVs)中,这会改变药物的细胞内运输。与游离药物相比,CmEV包裹的FF主要富集在溶酶体区室,通过损害溶酶体膜完整性导致坏死。由于血浆膜和溶酶体膜的稳定性由应激诱导的热休克蛋白70(Hsp70)维持,Hsp70与肿瘤特异性糖鞘脂具有很强的亲和力,坏死主要发生在膜Hsp70表达密度低于U87细胞的LN18细胞中。总之,我们的研究结果表明,当以游离药物或负载在仿生脂质囊泡中的药物形式存在时,肿瘤细胞的脂质代谢会影响FF的放射增敏能力。